Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease

Blood

Volumn 125, Issue 24, 2015, Pages 3805-3814

  Camus, Stéphane M ^a   De Moraes, João A ^a   Bonnin, Philippe ^b   Abbyad, Paul ^c   Le Jeune, Sylvain ^d   Lionnet, François ^e   Loufrani, Laurent ^f   Grimaud, Linda ^f   Lambry, Jean Christophe ^c   Charue, Dominique ^a   Kiger, Laurent ^a   Renard, Jean Marie ^a   Larroque, Claire ^g   Le Clésiau, Hervé ^g   Tedgui, Alain ^a   Bruneval, Patrick ^a   Barja Fidalgo, Christina ^h   Alexandrou, Antigoni ^c   Tharaux, Pierre Louis ^a   Boulanger, Chantal M ^a   Blanc Brude, Olivier P ^a   more..

^a INSERM   (France)

^b Université René Diderot   (France)

^c ECOLE POLYTECHNIQUE   (France)

^d AVICENNE HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITÉ D'ANGERS   (France)

^g Centres d'Examens de Santé   (France)

^h STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEME; HEMOGLOBIN; HEMOPEXIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; CAPILLARY ENDOTHELIUM; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROCYTE MEMBRANE; HUMAN; IMMUNOHISTOLOGY; IN VITRO STUDY; INTRAVASCULAR HEMOLYSIS; KIDNEY BIOPSY; MALE; MEMBRANE MICROPARTICLE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; C57BL MOUSE; COHORT ANALYSIS; COMPLICATION; ERYTHROCYTE; HEMOLYSIS; METABOLISM; PATHOLOGY; VASCULAR DISEASES;

ANEMIA, SICKLE CELL; ANIMALS; CELL-DERIVED MICROPARTICLES; COHORT STUDIES; ENDOTHELIAL CELLS; ERYTHROCYTES; HEME; HEMOLYSIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; VASCULAR DISEASES;

EID: 84931271446     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-589283     Document Type: Article

References (53)

1. Vallelian F, Schaer CA, Kaempfer T, et al. Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity. Blood. 2010;116(24):5347-5356.
2. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968;32(5):811-815.
3. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
4. Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol. 2008;142(1):126-135.
5. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86(2):123-154.
6. Willekens FL, Werre JM, Kruijt JK, et al. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. Blood. 2005;105(5):2141-2145.
7. Schaer CA, Vallelian F, Imhof A, Schoedon G, Schaer DJ. CD163-expressing monocytes constitute an endotoxin-sensitive Hb clearance compartment within the vascular system. J Leukoc Biol. 2007;82(1):106-110.
8. Tolosano E, Fagoonee S, Morello N, Vinchi F, Fiorito V. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal. 2010;12(2):305-320.
9. Schaer DJ, Alayash AI. Clearance and control mechanisms of hemoglobin from cradle to grave. Antioxid Redox Signal. 2010;12(2):181-184.
10. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol. 2007;18(2):414-420.
11. Nath KA, Katusic ZS. Vasculature and kidney complications in sickle cell disease. J Am Soc Nephrol. 2012;23(5):781-784.
12. Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol. 2004;76(3):245-251.
13. Nouraie M, Lee JS, Zhang Y, et al Walk-PHASST Investigators and Patients. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013;98(3):464-472.
14. Sabaa N, de Franceschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118(5):1924-1933.
15. Yang Y, Ohta K, Shimizu M, et al. Selective protection of renal tubular epithelial cells by heme oxygenase (HO)-1 during stress-induced injury. Kidney Int. 2003;64(4):1302-1309.
16. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-692.
17. Gladwin MT, Barst RJ, Castro OL, et al. Pulmonary hypertension and NO in sickle cell. Blood. 2010;116(5):852-854.
18. Nath KA, Grande JP, Haggard JJ, et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol. 2001;158(3):893-903.
19. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101(10):3953-3959.
20. Camus SM, Gausserès B, Bonnin P, et al. Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood. 2012;120(25):5050-5058.
21. Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001;97(6):1584-1589.
22. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107(2):271-278.
23. Lemogoum D, Van Bortel L, Najem B, et al. Arterial stiffness and wave reflections in patients with sickle cell disease. Hypertension. 2004;44(6):924-929.
24. Bains SK, Foresti R, Howard J, Atwal S, Green CJ, Motterlini R. Human sickle cell blood modulates endothelial heme oxygenase activity: effects on vascular adhesion and reactivity. Arterioscler Thromb Vasc Biol. 2010;30(2):305-312.
25. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809-4820.
26. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377-390.
27. Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014;123(24):3818-3827.
28. Allan D, Limbrick AR, Thomas P, Westerman MP. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature. 1982;295(5850):612-613.
29. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129(5):507-516.
30. Setty BN, Kulkarni S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 2000;96(3):1119-1124.
31. Mahfoudhi E, Lecluse Y, Driss F, Abbes S, Flaujac C, Garçon L. Red cells exchanges in sickle cells disease lead to a selective reduction of erythrocytes-derived blood microparticles. Br J Haematol. 2012;156(4):545-547.
32. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102(7):2678-2683.
33. van Tits LJ, van Heerde WL, Landburg PP, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun. 2009;390(1):161-164.
34. van Beers EJ, Schaap MC, Berckmans RJ, et al; CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009;94(11):1513-1519.
35. Bevers EM, Wiedmer T, Comfurius P, et al. Defective Ca(21)-induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study of the red blood cells of Scott syndrome. Blood. 1992;79(2):380-388.
36. Bratosin D, Estaquier J, Petit F, et al. Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death Differ. 2001;8(12):1143-1156.
37. Donadee C, Raat NJ, Kanias T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;124(4):465-476.
38. Leroyer AS, Ebrahimian TG, Cochain C, et al. Microparticles from ischemic muscle promotes postnatal vasculogenesis. Circulation. 2009;119(21):2808-2817.
39. Loufrani L, Levy BI, Henrion D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ Res. 2002;91(12):1183-1189.
40. Trudel M, Saadane N, Garel MC, et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J. 1991;10(11): 3157-3165.
41. Bonnin P, Sabaa N, Flamant M, Debbabi H, Tharaux PL. Ultrasound imaging of renal vasoocclusive events in transgenic sickle mice exposed to hypoxic stress. Ultrasound Med Biol. 2008;34(7):1076-1084.
42. Kosfeld MD, Frazier WA. Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin. J Biol Chem. 1993;268(12):8808-8814.
43. Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb. 1991;11(6):1700-1711.
44. Oztas Y, Durukan I, Unal S, Ozgunes N. Plasma protein oxidation is correlated positively with plasma iron levels and negatively with hemolysate zinc levels in sickle-cell anemia patients. Int J Lab Hematol. 2012;34(2):129-135.
45. Ozturk OH, Can Y, Yonden Z, et al. Lipoprotein subfraction profile and HDL-associated enzymes in sickle cell disease patients. Lipids. 2013;48(12):1217-1226.
46. LaBrake CC, Fung LW. Sickle hemoglobin is more fusogenic than normal hemoglobin at physiological pH and ionic strength conditions. Biochim Biophys Acta. 1998;1406(2):152-161.
47. Hebbel RP, Morgan WT, Eaton JW, Hedlund BE. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci USA. 1988;85(1):237-241.
48. Light WR III, Olson JS. The effects of lipid composition on the rate and extent of heme binding to membranes. J Biol Chem. 1990;265(26):15632-15637.
49. Light WR III, Olson JS. Transmembrane movement of heme. J Biol Chem. 1990;265(26):15623-15631.
50. Liu SC, Yi SJ, Mehta JR, et al. Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies. J Clin Invest. 1996;97(1):29-36.
51. Kuross SA, Rank BH, Hebbel RP. Excess heme in sickle erythrocyte inside-out membranes: possible role in thiol oxidation. Blood. 1988;71(4):876-882.
52. Liu SC, Zhai S, Palek J. Detection of hemin release during hemoglobin S denaturation. Blood. 1988;71(6):1755-1758.
53. Jarolim P, Lahav M, Liu SC, Palek J. Effect of hemoglobin oxidation products on the stability of red cell membrane skeletons and the associations of skeletal proteins: correlation with a release of hemin. Blood. 1990;76(10):2125-2131.